ArticleFrontiers in public health2026
Determinants of CD4 count recovery among severely immunosuppressed HIV patients initiated on antiretroviral therapy: a prospective cohort study in KwaZulu-Natal, South Africa.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For people living with HIV (PLWH), CD4 count serves as an effective indicator of response to antiretroviral therapy (ART) and a predictor of morbidity and mortality before and after ART initiation. In PLWH on ART, changes in CD4 count reflect immunological response to treatment. CD4 count recovery after ART initiation is defined as achieving a CD4 cell count of ≥500 cells/mm Materials and methods: Secondary data were collected by CAPRISA from June 2004 to August 2013, with monthly hospital visits. Time to CD4 recovery was calculated from ART initiation to the first CD4 count ≥500 cells/mm Results: Among 2,528 participants (median age 32 years), 1,803 had viral load <400 copies/mL, 1,589 were females, and 524 had TB. By the end of the study, 727 achieved CD4 recovery. Kaplan-Meier estimates showed median time to recovery of nearly 40 months for females and 59 months for males. The Weibull model outperformed the Cox model. Male participants had a 41% lower hazard of recovery than females [HR: 0.589, 95% CI: 0.497-0.698], while rural care was associated with a 49% higher hazard of recovery than urban settings [HR: 1.494, 95% CI: 1.228-1.818]. TB-coinfected participants had a 39.5% lower hazard [HR: 0.605, 95% CI: 0.489-0.748], whereas those with viral suppression had a 49% higher hazard of recovery [HR: 1.489, 95% CI: 1.213-1.826]. Conclusion: Delayed CD4 recovery among males, urban residents, TB-coinfected participants, and those with unsuppressed viral load (>400 copies/mL) underscores the need for targeted, differentiated HIV care strategies to accelerate immunological recovery and reduce HIV-related morbidity. Policymakers should prioritise male-focused interventions, strengthened TB-HIV integrated services, intensified adherence and viral load monitoring, and context-specific interventions in urban settings to accelerate immunological recovery and reduce HIV-related morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.